Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$25.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioNTech SE is a biotechnology company focused on developing and manufacturing immunotherapies for cancer and infectious diseases. With a market cap of $25 billion, it plays a significant role in the health care sector, especially in the context of vaccine development and personalized medicine.

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and help assess its financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In Q1 2026, BioNTech reported an EPS of -$2.28, which was better than the expected -$2.52, resulting in a positive surprise of 9.45%. However, the stock dropped 3.88% the following day, indicating market concerns despite the surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of BioNTech's upcoming earnings report, especially given the company's recent history of earnings misses. The market is looking for signs of recovery in profitability and revenue growth.

Bull Case

If BioNTech can demonstrate a significant improvement in its earnings and revenue, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to report losses and fails to meet expectations, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026, and how does it compare to previous quarters?

The EPS will be a key indicator of the company's financial recovery and will heavily influence investor sentiment.

What revenue figures can BioNTech provide for this quarter?

Revenue performance is critical for assessing market demand and the effectiveness of BioNTech's products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating BioNTech's potential for a turnaround, as recent improvements in R&D and product pipeline could lead to better-than-expected results.

Supporting Evidence

The company has a history of surprising on EPS, with a 63% beat rate in recent quarters.

Despite recent losses, there are signs of increased demand for innovative therapies that BioNTech is developing.

Key Risk

If the EPS comes in better than -$1.50, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether BioNTech can turn its financial performance around after a series of disappointing earnings.

Bull Confirmed If

An EPS improvement to -$1.50 or better would confirm a recovery in profitability.

Bear Confirmed If

An EPS of -$2.50 or worse would reinforce concerns about ongoing losses.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move following the earnings report, indicating heightened uncertainty among investors.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$5.5M

50,000 sh

1 insider

Net

$5.5M

Net selling

Most Active Insiders· 1 open-market trade

Chief Operating OfficerPoetting Sierk
$5.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential stock increase of around 2.09%, confirming a positive trend in recovery.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may remain volatile with mixed reactions.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of 7.43% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any new therapies in development.
2Management's outlook on market demand for their vaccines and therapies.
3Any changes in operational costs that could impact future profitability.
4Details on partnerships or collaborations that could enhance revenue streams.
5Insights into competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and help assess its financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioNTech can demonstrate a significant improvement in its earnings and revenue, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to report losses and fails to meet expectations, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026, and how does it compare to previous quarters?

The EPS will be a key indicator of the company's financial recovery and will heavily influence investor sentiment.

What revenue figures can BioNTech provide for this quarter?

Revenue performance is critical for assessing market demand and the effectiveness of BioNTech's products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating BioNTech's potential for a turnaround, as recent improvements in R&D and product pipeline could lead to better-than-expected results.

Supporting Evidence

The company has a history of surprising on EPS, with a 63% beat rate in recent quarters.

Despite recent losses, there are signs of increased demand for innovative therapies that BioNTech is developing.

Key Risk

If the EPS comes in better than -$1.50, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether BioNTech can turn its financial performance around after a series of disappointing earnings.

Bull Confirmed If

An EPS improvement to -$1.50 or better would confirm a recovery in profitability.

Bear Confirmed If

An EPS of -$2.50 or worse would reinforce concerns about ongoing losses.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move following the earnings report, indicating heightened uncertainty among investors.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$5.5M

50,000 sh

1 insider

Net

$5.5M

Net selling

Most Active Insiders· 1 open-market trade

Chief Operating OfficerPoetting Sierk
$5.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential stock increase of around 2.09%, confirming a positive trend in recovery.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may remain volatile with mixed reactions.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of 7.43% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any new therapies in development.
2Management's outlook on market demand for their vaccines and therapies.
3Any changes in operational costs that could impact future profitability.
4Details on partnerships or collaborations that could enhance revenue streams.
5Insights into competitive positioning within the biotechnology sector.